Cannabidiol pharmacotherapy for delta-9-tetrahidrocannabinol dependence / Cannabis de grado médico para el tratamiento de la dependencia a Δ-9-Tetrahidrocannabinol.

Addictions are one of the most important health problems worldwide. Within these disorders, cannabis is one of the psychoactive substances with more burden of morbidity and mortality worldwide. The actual knowledge about the effectiveness of treatments for cannabis use disorders is unsatisfactory. This review aims to explore the evidence on cannabidiol for the treatment of cannabis use disorder. There are several clinical pharmacotherapy trials researching cannabis use disorders with limited evidence. A smaller number of trials in animal models and humans on the use of cannabinoids, especially Cannabidiol and Tetrahydrocannabinol to treat cannabis dependence show evidence of reduction in days of use, withdrawal symptoms and craving. New trials are under development, and there is an urgent need for trials with larger numbers of patients and longer treatment periods to support possible indications in the near future.

Las adicciones son uno de los problemas de salud más importantes a nivel mundial. Dentro de estos trastornos, el cannabis es una de las sustancias psicoactivas que provoca mayor morbimortalidad a nivel mundial. La efectividad documentada de los tratamientos para los trastornos por uso de cannabis no es satisfactoria. Esta revisión tiene por objetivo explorar las evidencias sobre la implementación de tratamientos con cannabinoides para el abordaje de estos trastornos. La bibliografía actual cuenta con muchos ensayos sobre el uso de neuropsicofármacos en los trastornos por uso de cannabis con limitada evidencia a favor; mientras que un número más reducido de ensayos en modelos animales y en pacientes sobre el uso de cannabinoides, en especial Cannabidiol y Tetrahidrocannabinol para tratar dicha dependencia muestran evidencias de reducción en días de consumo, síntomas de abstinencia y craving. Se encuentran en desarrollo nuevos ensayos clínicos, estos son una necesidad imperiosa para proveer mayor número de pacientes y con períodos de tratamiento más prolongados y así poder explorar más a fondo su posible indicación en un futuro cercano.

[Improved cognitive performance and post-injury plasticity during intensive outpatient treatment for substance use disorder. A case report]. / Mejoramiento del rendimiento cognitivo y plasticidad post lesional durante el tratamiento ambulatorio intensivo por trastorno por uso de sustancias. Reporte de caso.

There are different degrees of cognitive functional decline and modifiable risk factors related to their evolution. Mild cognitive impairment is a state of cognitive function between that seen in normal aging and dementia and is related to an increased risk of developing dementia. Among its potentially modifiable risk factors, substance use disorders have been described. In particular, techniques with predictive value have been developed to identify this impairment during neuropsychological assessment. We present a clinical case of a young patient with mild cognitive deficit and multiple drug abuse who after 24 months of an intensive outpatient treatment showed improvement in cognitive screening scores and neuroimaging. Together with other modifiable lifestyle factors, early cognitive screening in patients with substance use disorder could be a tool to detect other dimensions affected and contribute with specific therapies that promote post-injury plasticity and overall patient improvement.